Global Biodefense Market Size, Status and Forecast 2021-2027


Biodefense market refers to the pharmaceuticals, vaccines and antibodies applied in the treatment of a wide range of infectious diseases, whether those diseases emerge naturally or are deliberately introduced as an act of bioterrorism. Biodefense products generally defense against anthrax, smallpox, botulism, radiation/nuclear disasters and other disasters.

In the wake of the 2001 anthrax attacks, the U.S. government set out on a bold path to improve the country?s preparedness for bioterrorism by developing and stockpiling new drugs and vaccines to protect Americans from health emergencies. Since 2004, the US government has provided assistance in the development and manufacturing of products in order to maintain its Strategic National Stockpile (SNS) to counter any bioterror attack.

USA is still the largest supplier and consumption market due to the highly developed pharmaceuticals technology and increased awareness of the threat of global terror activity. In 2015, USA enjoyed over 80% consumption market.


In 2021, the global Biodefense market size will be US$ 1144 million and it is expected to reach US$ 1746 million by the end of 2027, with a CAGR of 7.3% during 2021-2027.

This report focuses on the global Biodefense status, future forecast, growth opportunity, key market, and key players. The study objectives are to present the Biodefense development in North America, Europe, Japan, China, Southeast Asia, India, etc.

Global Biodefense Scope and Market Size

Biodefense market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Biodefense market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type

  • Anthrax
  • Smallpox
  • Botulism
  • Radiation/Nuclear
  • Others

Segment by Application

  • US Military Market
  • US Civilian Market
  • Non – US Market

By Region

  • North America
  • Europe
  • Japan
  • China
  • Southeast Asia
  • India

By Company

  • Emergent Biosolutions
  • Hytest
  • GSK
  • Sanofi
  • PharmAthene
  • Bavarian Nordic
  • SIGA Technologies
  • Arbutus Biopharma
  • DynPort Vaccine
  • Xoma Corporation
  • Ichor Medical Systems
  • Aeolus Pharmaceuticals
  • Achaogen
  • Elusys Therapeutics
  • Dynavax Technologies
  • Cleveland BioLabs
  • Soligenix
  • Alnylam Pharmaceuticals

Table of content

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Biodefense Market Size Growth Rate by Type (2021-2027)
1.2.2 Anthrax
1.2.3 Smallpox
1.2.4 Botulism
1.2.5 Radiation/Nuclear
1.2.6 Others
1.3 Market by Application
1.3.1 Global Biodefense Market Share by Application (2021-2027)
1.3.2 US Military Market
1.3.3 US Civilian Market
1.3.4 Non – US Market
1.4 Study Objectives
1.5 Years Considered

2 Executive Summary
2.1 Global Biodefense Market Size
2.2 Biodefense Market Size by Regions
2.2.1 Biodefense Growth Rate by Regions (2021-2027)
2.2.2 Biodefense Market Share by Regions (2021-2027)
2.3 Industry Trends
2.3.1 Market Top Trends
2.3.2 Market Use Cases

3 Key Players
3.1 Biodefense Revenue by Players (2020-2021)
3.2 Biodefense Key Players Headquaters and Area Served
3.3 Key Players Biodefense Product/Solution/Service
3.4 Date of Enter into Biodefense Market
3.5 Mergers & Acquisitions, Expansion Plans

4 Breakdown by Type and by Application
4.1 Global Biodefense Market Size by Type (2021-2027)
4.2 Global Biodefense Market Size by Application (2021-2027)

5 North America
5.1 North America Biodefense Market Forecast (2021-2027)
5.2 Biodefense Key Players in North America
5.3 North America Biodefense Market Size by Type
5.4 North Americ

276 5th Avenue, New York , NY 10001,United States
International: (+1) 646 781 7170 / +91 8087042414

Follow Us On linkedin :-